| Patient | Clara Barton |
|---|---|
| Date of birth | 1973-12-25 |
| Identifiers | MRN HR-NI024-SYN; SSN (made up) 000-24-3357 |
| Document date | 2026-02-03 |
| Author | Eleanor Whitcombe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week sertraline tolerability and safety check; psychiatry consultation today. [S]
Ms. Barton returns two weeks after starting sertraline 50 mg each morning for a recurrent depressive episode. She took the two weeks of medical leave and has not been to the office, though she admits to answering some messages from home. She had mild nausea and loose stools in the first week, which have settled; she has had no headache, restlessness, agitation, or bleeding. She has missed no doses. She still wakes at 3 or 4 in the morning but now sleeps four to five hours. Her energy and interest are still low, though she walked with a friend twice this week. She has had no suicidal thoughts since the first visit and keeps her safety plan in her bag. Her first cognitive behavioral therapy session is booked for this week. She saw Dr. Mendes of psychiatry this morning. [S]
| Element | Detail |
|---|---|
| Medication tolerance | Mild nausea and loose stools in week one, now settled; no agitation or restlessness |
| Adherence | No missed doses |
| Sleep | Four to five hours, with early waking |
| Work | On two weeks of medical leave; answering some messages from home |
| Safety | No suicidal thoughts since intake; safety plan carried |
| PHQ-9 | 16, down from 18 |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Early nausea and loose stools resolved; no bleeding |
| Neurological | Negative | No headache, tremor, or restlessness |
| Constitutional | Positive | Fatigue persists; appetite slightly better |
| Psychiatric | Positive | Low mood and interest, early waking; no suicidal thoughts, elevated mood, or racing thoughts |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-01-20 to 2026-03-03 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-03 | Body height | 152 | cm | S |
| 2026-02-03 | Body weight | 49.6 | kg | S |
| 2026-02-03 | Body mass index (BMI) [Ratio] | 21.5 | kg/m2 | S |
| 2026-02-03 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-02-03 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-02-03 | Heart rate | 78 | /min | S |
| 2026-02-03 | Respiratory rate | 14 | /min | S |
| 2026-02-03 | Body temperature | 36.5 | Cel | S |
| 2026-02-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 16 | {score} | S |
Vital signs recorded on 2026-02-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Small, neatly dressed, tired |
| Mental status | Alert and cooperative; speech soft and slow; mood "a little less heavy"; affect constricted; thought process linear; no suicidal ideation; no psychotic features; insight and judgment good |
| Neurological | No tremor |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Major depressive disorder, recurrent, moderate (moderately severe symptoms at intake), after a prolonged humanitarian deployment; synthetic modern diagnosis linked to her documented periods of depression and nervous prostration | active | confirmed | F33.1 | S — Synthetic modern diagnosis. Her periods of depression and nervous prostration are documented in her own words (D); calling them major depression is a retrospective interpretation (R), and no diagnosis was made in her lifetime. |
| Occupational burnout after eighteen months leading field medical relief in a war zone | active | confirmed | Z73.0 | S — Synthetic contributing factor echoing her documented exhaustion after wartime relief work; burnout is an occupational phenomenon, not a mental disorder. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 16, down from 18 at intake (11 percent) |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Completed today | Early nausea and loose stools settled; no activation, agitation, or bleeding |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since intake; PHQ-9 item 9 scored 0. Protective factors unchanged. Safety plan reviewed: she carries her copy and has 988 and the clinic number saved |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no headache, tremor, sexual side effects, or bleeding |
| Survey | Bipolar screen at the initial workup | Once, at the initial depression workup | Completed today | Psychiatric interview today found no past manic or hypomanic episode; no Mood Disorder Questionnaire score is recorded |
| Referral | Psychiatry consultation | For recurrent or complex episodes | Completed today | Seen today; diagnosis confirmed; combination treatment and titration plan agreed |
| Self-management | Psychotherapy, sleep, activity, and social contact | Every visit during active treatment | Completed today | CBT starts this week; two walks with a friend; sleep four to five hours |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Depression review in four weeks, six weeks after starting sertraline. Next scheduled visit 2026-03-03: six-week depression treatment review. [S]